The pharmacologic management of premenstrual dysphoric disorder

Bibliography

• American Psychiatric Association. Premenstrual dysphoric disorder. In: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. American Psychiatric Association, Washington, DC, USA; 2000. p. 771-4
   Google Scholar
• American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin; 2000. Number 15
   Google Scholar
• Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007;23(3):123-30
   PubMed Web of Science ®Google Scholar
• Johnson SR, Mcchesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988;33(4):340-6
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32(1):119-32
   PubMed Web of Science ®Google Scholar
• Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Practical Strategies in Obstetrics and Gynecology. Ransom SB, editor. Philadelphia: WB Saunders Company; 2000. p. 684-94
   Google Scholar
• Freeman EW. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics 2005;23(5):433-44
   PubMed Web of Science ®Google Scholar
• Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006;15(1):57-69
   PubMed Web of Science ®Google Scholar
• Futterman LA, Rapkin AJ. Diagnosis of premenstrual disorders. J Reprod Med 2006;51(4 Suppl):349-58
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990;20(2):129-34
   PubMed Web of Science ®Google Scholar
• Praschak-Rieder N, Willeit M, Neumeister A, et al. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 2001;63(1-3):239-42
   PubMed Web of Science ®Google Scholar
• Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993;29(2-3):193-200
   PubMed Web of Science ®Google Scholar
• Bancroft J, Rennie D, Warner P. Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom Med 1994;56(3):225-31
   PubMed Web of Science ®Google Scholar
• Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003;28(Suppl 3):55-99
   Web of Science ®Google Scholar
• Joffee H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-30
   PubMed Web of Science ®Google Scholar
• Backstrom T, Andersson A, Andree L, et al. Pathogenesis in menstrual cycle-linked disorders. Ann NY Acad Sci 2003;1007:42-53
   PubMed Web of Science ®Google Scholar
• Treolar S, Heath A, Martin N. Genetic and Environmental Influences on premenstrual symptoms in an Australian twin sample. Psychol Med 2002;32:25-38
   PubMed Web of Science ®Google Scholar
• Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993;162:481-6
   PubMed Web of Science ®Google Scholar
• Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988;158(1):5-11
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338(4):256-7
   PubMed Web of Science ®Google Scholar
• Bethea CL. Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology 1994;60(1):50-61
   PubMed Web of Science ®Google Scholar
• Graeff FG, Guimaraes FS, De Andrade TG, et al. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996;54(1):129-41
   PubMed Web of Science ®Google Scholar
• Jenike MA, Rauch SL, Cummings JL, et al. Recent developments in neurobiology of obsessive-compulsive disorder. J Clin Psychiatry 1996;57:492-503
   PubMedGoogle Scholar
• Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003;417:38-50
   PubMedGoogle Scholar
• Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987;70(4):533-7
   PubMed Web of Science ®Google Scholar
• Clayton AH, Keller AE, Leslie C, et al. Exploratory study of premenstrual symptoms and serotonin variability. Arch Womens Ment Health 2006;9(1):51-7
   PubMed Web of Science ®Google Scholar
• Rasgon N, McGuire M, Tanavoli S, et al. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 2000;73(1):144-9
   PubMed Web of Science ®Google Scholar
• Jovanovic H, Cerin A, Karlsson P, et al. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006;148(2-3):185-93
   PubMed Web of Science ®Google Scholar
• Eriksson O, Wall A, Marteinsdottir I, et al. Mood changes correlate to changes in brain serotonin precursor trafficking them with premenstrual dysphoria. Psychiatry Res 2006;146(2):107-6
   PubMed Web of Science ®Google Scholar
• Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002;4:CD001396
   Google Scholar
• Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994;32(1):37-44
   PubMed Web of Science ®Google Scholar
• Roca CA, Schmidt PJ, Smith MJ, et al. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002;159(11):1876-81
   PubMed Web of Science ®Google Scholar
• Eriksson E, Hedberg M, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropharmacology 1995;12(2):167-76
   Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999;56(10):932-9
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmachol 1997;17:261-6
   PubMed Web of Science ®Google Scholar
• Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986;232(4753):1004-7
   PubMed Web of Science ®Google Scholar
• Rabow LE, Russek SJ, Farb DH. From ion currents to genomic analysis: recent advances in GABAA receptor research. Synapse 1995;21(3):189-274
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997;90(5):709-14
   PubMed Web of Science ®Google Scholar
• Sundström Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003;6(1):23-41
   PubMedGoogle Scholar
• Smith SS. Withdrawal properties of a neuroactive steroid: implications for GABAA receptor gene regulation in the brain and anxiety behavior. Steroids 2002;67(6):519-28
   PubMed Web of Science ®Google Scholar
• Smith SS, Gong QH, Li X, et al. Withdrawal from 3alpha-OH-5alpha-pregnan-20-One using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor alpha4 subunit in association with increased anxiety. J Neurosci 1998;18:5275-84
   PubMed Web of Science ®Google Scholar
• Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990;47(3):270-5
   PubMed Web of Science ®Google Scholar
• Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987;70(1):37-43
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274(1):51-7
   PubMed Web of Science ®Google Scholar
• Stell BM, Brickley SG, Tang CY, et al. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci USA 2003;100(24):144439-44
   Google Scholar
• Epperson CN, Haga K, Mason GF, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002;59(9):851-8
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106(3):492-501
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72(6):414-21
   PubMed Web of Science ®Google Scholar
• Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007;109(5):1068-75
   PubMed Web of Science ®Google Scholar
• Soares CN, Cohen LS. Association between premenstrual syndrome and depression. J Clin Psychiatry 2000;61(9):677-8
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W. Daily record of Severity of Problems (DRSP) reliability and validity. Arch Womens Ment Health 2005;9(1):41-9
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999;156(9):1403-8
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Holthausen GA, Poschman K, et al. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006;26(2):198-202
   PubMed Web of Science ®Google Scholar
• Van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003;165(2):97-110
   PubMed Web of Science ®Google Scholar
• Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95(6):3239-44
   PubMed Web of Science ®Google Scholar
• Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991;52:290-3
   PubMed Web of Science ®Google Scholar
• Wood SH, Mortola JF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992;80:339-44
   PubMed Web of Science ®Google Scholar
• Menkes DB, Taghavi E, Mason PA, et al. Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992;305(6849):346-7
   PubMed Web of Science ®Google Scholar
• Steiner M, Steinberg S, Stewart D, et al. Fluxoetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332(23):1529-34
   PubMed Web of Science ®Google Scholar
• Ozeren S, Corakci A, Yucesoy I, et al. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1997;73:167-70
   PubMed Web of Science ®Google Scholar
• Su TP, Schmidt PJ, Danaceau M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997;82(4):1220-8
   PubMed Web of Science ®Google Scholar
• Steiner M, Romano SJ, Babcock S, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001;108(5):462-8
   PubMed Web of Science ®Google Scholar
• Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003;6:203-9
   PubMedGoogle Scholar
• Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278(12):983-8
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sondheimer SJ, Polansky M, et al. Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry 2000;61(8):579-84
   PubMedGoogle Scholar
• Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004;66(5):707-13
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Bellew K, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005;7(2):53-60
   PubMedGoogle Scholar
• Landen M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine on premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-61
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98(5 Pt 1):737-44
   PubMed Web of Science ®Google Scholar
• Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100(3):435-44
   PubMed Web of Science ®Google Scholar
• Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24(3):417-33
   PubMed Web of Science ®Google Scholar
• Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58(9):399-402
   PubMed Web of Science ®Google Scholar
• Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998;59(2):76-80
   PubMed Web of Science ®Google Scholar
• Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8(4):328-32
   PubMedGoogle Scholar
• Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193(2):352-60
   PubMed Web of Science ®Google Scholar
• Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18(5):390-8
   PubMed Web of Science ®Google Scholar
• Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993;9:133-45
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004;161(2):343-51
   PubMed Web of Science ®Google Scholar
• Freeman E, Rickels K, Arrendondo F, et al. Full or half-cycle treatment of severe premenstrual syndrome with a seratonergic antidepressant. J Psychopharmacol 1990;19(1):3-8
   Google Scholar
• Steiner M, Ravindran A, Lemelledo JM, et al. Luteal-phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo controlled trial in Canadian women. Can J Psychiatry 2006 (In Press)
   Google Scholar
• Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005;66(6):769-73
   PubMed Web of Science ®Google Scholar
• Veeninga AT, Westernberg HG, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology (Berl) 1990;102(3):414-6
   PubMed Web of Science ®Google Scholar
• Landen M, Eriksson O, Sunblad C, et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001;155(3):292-8
   PubMed Web of Science ®Google Scholar
• Sundblad C, Modighk, Andersch B, et al. Clomipraine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992;85:39-47
   PubMed Web of Science ®Google Scholar
• Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994;84(3):379-85
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993;50(6):467-73
   PubMed Web of Science ®Google Scholar
• Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989;1:777
   PubMed Web of Science ®Google Scholar
• Hammarbäck S, Ekholm UB, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with premenstrual syndrome. Acta Endocrinol (Copenh) 1991;125(2):132-7
   PubMedGoogle Scholar
• Bäckström T, Hansson-Malmström Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992;46(3):253-68
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Biggio G, Concas A. Oral contraceptives and neuroactive steroids. Pharmacol Biochem Behav 2006;84(4):628-34
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C. Hormonal withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95(2):261-6
   PubMed Web of Science ®Google Scholar
• Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999;72(1):115-20
   PubMed Web of Science ®Google Scholar
• Muhn P, Krattemacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995;51(2):99-110
   PubMed Web of Science ®Google Scholar
• Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5(2):124-34
   PubMedGoogle Scholar
• Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 2005;71(1):1-7
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Christiansen E, Evans WS, et al. Physiological profiles of episodic progesterone release during the midluteal phase of the human menstrual cycle: analysis of circadian and ultradian rhythms, discrete pulse properties, and correlations with simultaneous luteinizing hormone release. J Clin Endocrinol Metab 1988;66(2):414-21
   PubMed Web of Science ®Google Scholar
• Muse KN, Cetel NS, Futterman LA, et al. The premenstrual syndrome: effects of ‘medical ovariectomy’. N Engl J Med 1984;311:1345-9
   PubMed Web of Science ®Google Scholar
• Brown CS, Ling FW, Anderson RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994;84:779-86
   PubMed Web of Science ®Google Scholar
• Leather AT, Studd JWW, Watson NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999;13(1):48-55
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sondheimer SJ, Rickels K. Gonadotrophin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997;33(2):303-9
   PubMed Web of Science ®Google Scholar
• Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotrophin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991;71:252A-252F
   Web of Science ®Google Scholar
• Di Carlo C, Palomba S, Tommaselli GA, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001;75(2):380-4
   PubMed Web of Science ®Google Scholar
• Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004;111(6):585-93
   PubMed Web of Science ®Google Scholar
• Sundström I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-relasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999;78(10):891-9
   PubMed Web of Science ®Google Scholar
• Mitwally FMM, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 2002;9(4):236-41
   PubMed Web of Science ®Google Scholar
• Pierce JS, Gazvani R, Farquharson RG. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 2000;74(5):964-8
   PubMed Web of Science ®Google Scholar
• Sarno AP, Miller EJ, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987;70(1):33-6
   PubMed Web of Science ®Google Scholar
• Watts JF, Butt WR, Logan Edwards RL. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987;94:30-4
   PubMedGoogle Scholar
• Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995;20(2):193-209
   PubMed Web of Science ®Google Scholar
• Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;2:730-2
   PubMed Web of Science ®Google Scholar
• Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102(6):475-84
   PubMedGoogle Scholar
• Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362(9391):428-32
   PubMed Web of Science ®Google Scholar
• Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131-6
   PubMed Web of Science ®Google Scholar
• Halbreich U, O'Brien PM, Eriksson E, et al. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs 2006;20(7):523-47
   PubMed Web of Science ®Google Scholar
• Preston JD, O'Neal JH, Talaga MC. Antidepressant Medications. In: Handbook of Clinical Psychopharmacology for Therapists, 3rd Edition. Oakland, CA: New Harbinger Publications, Inc., 2002. p. 163-80
   Google Scholar
• Gitlin MJ. Psychotropic medications and their effects on sexual function. J Clin Psychiatry 1995;56(11):536-7
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass RH, Kase NG. Steroid contraception. In: Clinical Gynecologic Endocrinology and Infertility. Williams and Wilkins, Baltimore; 1999
   Google Scholar
• Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75(5):328-36
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heineman LA. European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903]. BMC Womens Health 2006;6:1-7
   PubMedGoogle Scholar
• Schurmann R, Blode H, Benda N, et al. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal and impaired renal function. J Clin Pharmacol 2006;46(8):867-75
   PubMed Web of Science ®Google Scholar
• Yasmin (drospirenone and ethinyl estradiol) [prescribing information]; Montville, NJ: Berlex, Inc.; October 2005
   Google Scholar
• Yaz (drospirenone and ethinyl estradiol) [prescribing information]; Montville, NJ: Berlex, Inc.; October 2007
   Google Scholar
• Dickerson V. Premenstrual syndrome and premenstrual dysphoric disorder: individalizing therapy. Female Patient 2007;32(1):38-46
   Google Scholar
• US Food and Drug Administration website updated; 2007. Available from: http://www.fda.gov/cder/drug/antidepressants/default.htm
   Google Scholar
• Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106(2):219-26
   PubMed Web of Science ®Google Scholar
• Sundström-Poromaa I, Bixo M, Björn I, et al. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol 2000;21(4):205-11
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007;196(4):412-6; discussion 412.e6
   PubMed Web of Science ®Google Scholar